Freenome launches SimpleScreen Lung, offers single-draw lung+CRC screening with strong validation metrics
Freenome launched SimpleScreen Lung, a blood test for lung cancer screening in adults 50-80 with a 20+ pack-year smoking history. It can be ordered alone or with the FDA-approved SimpleScreen CRC. In a study, it achieved 85% sensitivity at 50% specificity and 99.8% NPV. Stage-specific sensitivities ranged from 82% to 94%. The company filed an 8-K with the SEC on October 20, 2026.
How this was made
The 30-second read
Why it matters
The new SimpleScreen Lung test expands Freenome's portfolio beyond colorectal cancer, potentially opening new payer and provider markets.
Market read
First disclosure of a commercial lung‑cancer screening product with strong validation metrics; could drive short‑term price movement.
What to watch
Regulatory pathway for the LDT and competition from established screening modalities could temper upside.
Background
Freenome is a clinical‑stage genomics company focused on early cancer detection using blood‑based assays.
Ticker impact
Freenome filed an 8‑K announcing the launch of SimpleScreen Lung, a new single‑draw blood test with 85% sensitivity and 99.8% NPV.
likely upside as the market prices in future revenue from lung‑cancer screening contracts.
First‑time disclosure of clinical performance metrics and a commercial offering; investors typically reward biotech firms that move from research to marketable tests.
Market effects
May boost sentiment for liquid‑biopsy and early‑cancer detection companies.
Primarily U.S. biotech sector, with limited immediate global effect.
Limited; relevance confined to investors tracking early‑diagnostic biotech.
Counterpoint
If the test fails to secure payer reimbursement or large‑scale contracts, the hype could fade quickly.
Key entities
- companyFreenome, Inc.
US‑listed biotech developing blood‑based cancer screening tests.
